Bayer CropScience (506285) Q4 07/08 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 07/08 earnings summary
19 Oct, 2026Executive summary
Fifteen-month period ended 31 Mar 2008; sales and operating income reached Rs 12,383.20m, while profit after tax was Rs 491.03m, down from Rs 568.58m for the prior 12-month period. Periods are not comparable.
Profit before tax was Rs 679.56m; before exceptional items, it was Rs 790.53m.
Financial highlights
Sales and operating income were Rs 12,383.20m versus Rs 7,746.50m; the current period covers 15 months versus 12 months previously.
Profit before tax was Rs 679.56m versus Rs 890.53m, and profit after tax was Rs 491.03m versus Rs 568.58m; comparisons span different period lengths.
Exceptional items comprised Rs 194.02m profit on long-term investment sales and Rs 304.99m voluntary retirement expenditure, net expense Rs 110.97m.
Export turnover on an FOB basis was Rs 1,423.62m versus Rs 1,233.30m in the previous 12-month period.
Outlook and guidance
Planned 2008 launches included Sectin 60 WG fungicide for potato and grape and Regent 80 WG insecticide for rice; approvals were also being pursued for existing products on additional crops.
Product development targeted crop protection, environmental science, fruits and vegetables, and new green, turf and industrial vegetation management segments.
Environmental Science plans included Aqua K-Othrine for space spraying, plus ant gel, rodenticide and turf weed-control products.
Latest events from Bayer CropScience
- CropScience scale expanded through merger, while one-offs weighed on reported earnings.506285
Q4 2003 - Drought drove a sharp earnings decline, while export and specialty-business growth offered offsets.506285
Q4 2002 - PBT improved, but adjusted earnings faced portfolio, monsoon and pricing headwinds.506285
Q4 2004 - PAT rose 41% as market share advanced to 16% despite a 12% industry decline.506285
Q4 2005 - Profit rose as new products and seed distribution broadened growth plans; Thane closures triggered impairment.506285
Q4 2006 - PAT reached Rs. 944.59 million as new products met rising crop-protection demand.506285
Q4 08/09 - Sales and PAT rose as new launches supported growth amid pricing and operational risks.506285
Q4 09/10 - Revenue advanced and PAT grew modestly as innovation-led expansion met pricing and regulatory risks.506285
Q4 10/11 - Revenue and PAT rose despite a ₹579m Thane remediation charge.506285
Q4 11/12